A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients

Asian Journal of Surgery

Aihua Wu¹  Shuyu Fang²  Yijun Mo²  Yanqing Liu²  Xinjian Li²  Shanshan Wang³ 

[1] Corresponding author. Department of Clinical Laboratory, 59 Liuting Street, Ningbo First Hospital, Ningbo, 315010, Zhejiang, China.;Department of Clinical Laboratory, Ningbo First Hospital, Ningbo, Zhejiang, China;Department of Thoracic Surgery, Ningbo First Hospital, Ningbo, Zhejiang, China;

关键词: Programmed cell death ligand 1;    Non-small cell lung cancer;    Gene mutations;    EGFR;    KRAS;    TP53;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objectives: To investigate the associations among expression of programmed cell death ligand 1 (PD-L1), eleven mutated genes, and clinicopathological characteristics in 273 patients with non-small cell lung cancer (NSCLC). Methods: We retrospectively examined tumor PD-L1 expression in 247 surgically resected primary and 26 advanced NSCLC patients by immunohistochemistry using SP263 antibody assay. Gene mutations of EGFR, TP53, KRAS, PIK3CA, ERBB2, MET, RET, ALK, BRAF, ROS1, and APC were examined by NGS sequence. Data analysis was carried out using SPSS 22.0. The associations among PD-L1 expression, eleven mutated genes and clinicopathological characteristics were assessed by univariate and multivariate analysis. Results: Among the total 273 patients, 68 (24.9%) patients were positive for PD-L1 expression. Data showed that mutated rate of EGFR gene was the highest with 63.0% (172/273), followed by TP53 (11.7%, 32/273) and KRAS (5.5%, 15/273). The female, non-smoker, and patients with adenocarcinoma (ADC) were more likely to have EGFR mutations. Multivariate logistic regression showed that PD-L1 expression was significantly associated with Non-ADC, lymphatic invasion, EGFR wild type and TP53 mutation (p = 0.041, <0.001, 0.004 and 0.014, respectively). Moreover, PD-L1 expression in adenocarcinoma was associated with lymphatic invasion, mutation of TP53 and KRAS gene (p = 0.012, <0.025 and 0.041, respectively). Conclusions: Mutations of EGFR, KRAS and TP53 should be routinely detected in clinical practice to better guide the immunotherapy for NSCLC patients. Future investigations are warranted to illustrate the potential mechanisms between driver mutations and PD-L1 expression for guiding immunotherapy in patients with NSCLC.

【 授权许可】

Unknown